Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness

An Editorial Expression of Concern to this article was published on 19 July 2023

This article has been updated

Abstract

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers. We have recently reported that suppression of CEACAM6 expression impairs pancreatic adenocarcinoma progression in vivo. In order to characterize the mechanisms through which CEACAM6 influences the malignant phenotype, CEACAM6-overexpressing Capan2 pancreatic adenocarcinoma cells were established by stable transfection. We determined the effect of CEACAM6 overexpression on cellular invasiveness towards insulin-like growth factor I (IGF-I), a peptide of critical importance in pancreatic cancer malignant cellular behavior and tumor progression. IGF-I-induced cellular invasiveness and IGF-IR expression were significantly increased in clones overexpressing CEACAM6. Using inhibitory anti-IGF-IR antibody, a requirement for IGF-IR signaling in the enhanced invasiveness towards IGF-I induced by CEACAM6 overexpression was confirmed. CEACAM6-overexpressing clones exhibited increased Akt and c-Src kinase activities, as well as higher levels of matrix metalloproteinase-2 (MMP-2) expression and activity in the presence of IGF-I. While Akt kinase is both necessary and sufficient to induce IGF-IR upregulation, c-Src kinase activity is necessary, but alone is insufficient to upregulate IGF-IR expression. CEACAM6 is an important determinant of pancreatic adenocarcinoma malignant cellular behavior and, together with its downstream targets, warrants further investigation as a therapeutic target in this disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Change history

References

  • Baserga R, Hongo A, Rubini M, Prisco M and Valentinis B . (1997). Biochim. Biophys. Acta, 1332, F105–F126.

  • Baserga R, Sell C, Porcu P and Rubini M . (1994). Cell Prolif., 27, 63–71.

  • Bergmann U, Funatomi H, Yokoyama M, Beger HG and Korc M . (1995). Cancer Res., 55, 2007–2011.

  • Berrozpe G, Schaeffer J, Peinado MA, Real FX and Perucho M . (1994). Int. J. Cancer, 58, 185–191.

  • Brodt P, Fallavollita L, Khatib AM, Samani AA and Zhang D . (2001). J. Biol. Chem., 276, 33608–33615.

  • Burfeind P, Chernicky CL, Rininsland F, Ilan J and Ilan J . (1996). Proc. Natl. Acad. Sci. USA, 93, 7263–7268.

  • Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT and Mukhopadhyay D . (2000). J. Biol. Chem., 275, 20700–20706.

  • Downward J . (1998). Curr. Opin. Cell Biol., 10, 262–267.

  • Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC . (1998). Cancer Res., 58, 3353–3361.

  • Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE . (2004). Oncogene, 23, 465–473.

  • Ellenrieder V, Adler G and Gress TM . (1999). Ann. Oncol., 10 (Suppl 4), 46–50.

  • Flossmann-Kast BB, Jehle PM, Hoeflich A, Adler G and Lutz MP . (1998). Cancer Res., 58, 3551–3554.

  • Gardner-Thorpe J, Ito H, Ashley SW and Whang EE . (2002). Biochem. Biophys. Res. Commun., 293, 391–395.

  • Guirouilh J, Castroviejo M, Balabaud C, Desmouliere A and Rosenbaum J . (2000). Int. J. Oncol., 17, 777–781.

  • Hasegawa T, Isobe K, Tsuchiya Y, Oikawa S, Nakazato H, Nakashima I and Shimokata K . (1993). Br. J. Cancer, 67, 58–65.

  • Ilantzis C, DeMarte L, Screaton RA and Stanners CP . (2002). Neoplasia, 4, 151–163.

  • Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW and Whang EE . (2003). Surgery, 134, 221–226.

  • Jiang T and Qiu Y . (2003). J. Biol. Chem., 278, 15789–15793.

  • Kaleko M, Rutter WJ and Miller AD . (1990). Mol. Cell. Biol., 10, 464–473.

  • Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K and Riethmuller G . (1993). Oncogene, 8, 289–298.

  • Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW and Martin GR . (1986). Biochemistry, 25, 312–318.

  • Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K and Martin GR . (1982). Biochemistry, 21, 6188–6193.

  • Kodera Y, Isobe K, Yamauchi M, Satta T, Hasegawa T, Oikawa S, Kondoh K, Akiyama S, Itoh K and Nakashima I . (1993). Br. J. Cancer, 68, 130–136.

  • Kuroki M, Abe H, Imakiirei T, Liao S, Uchida H, Yamauchi Y, Oikawa S and Kuroki M . (2001). J. Leukoc. Biol., 70, 543–550.

  • Lazar-Molnar E, Hegyesi H, Toth S and Falus A . (2000). Cytokine, 12, 547–554.

  • Li SL, Liang SJ, Guo N, Wu AM and Fujita-Yamaguchi Y . (2000). Cancer Immunol. Immunother., 49, 243–252.

  • Lohr M, Trautmann B, Gottler M, Peters S, Zauner I, Maillet B and Kloppel G . (1994). Br. J. Cancer, 69, 144–151.

  • Long L, Navab R and Brodt P . (1998a). Cancer Res., 58, 3243–3247.

  • Long L, Nip J and Brodt P . (1994). Cancer Res., 54, 3732–3737.

  • Long L, Rubin R and Brodt P . (1998b). Exp. Cell Res., 238, 116–121.

  • Macaulay VM . (1992). Br. J. Cancer, 65, 311–320.

  • Mayne KM, Pulford K, Jones M, Micklem K, Nagel G, van der Schoot CE and Mason DY . (1993). Br. J. Haematol., 83, 30–38.

  • Mira E, Manes S, Lacalle RA, Marquez G and Martinez A . (1999). Endocrinology, 140, 1657–1664.

  • Murphy LO, Cluck MW, Lovas S, Otvos F, Murphy RF, Schally AV, Permert J, Larsson J, Knezetic JA and Adrian TE . (2001). Br. J. Cancer, 84, 926–935.

  • Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H and Schmiegel W . (1996). Gastroenterology, 110, 1215–1224.

  • Ordonez C, Screaton RA, Ilantzis C and Stanners CP . (2000). Cancer Res., 60, 3419–3424.

  • Ouban A, Muraca P, Yeatman T and Coppola D . (2003). Hum. Pathol., 34, 803–808.

  • Park BK, Zeng X and Glazer RI . (2001). Cancer Res., 61, 7647–7653.

  • Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D and Baserga R . (1993). Cancer Res., 53, 1102–1106.

  • Prisco M, Hongo A, Rizzo MG, Sacchi A and Baserga R . (1997). Mol. Cell. Biol., 17, 1084–1092.

  • Raitano AB, Scuderi P and Korc M . (1990). Pancreas, 5, 267–277.

  • Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R and Rubin R . (1994). Cancer Res., 54, 2218–2222.

  • Scholzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B and Thompson J . (2000). Am. J. Pathol., 156, 595–605.

  • Sell C, Baserga R and Rubin R . (1995). Cancer Res., 55, 303–306.

  • Shanmugathasan M and Jothy S . (2000). Pathol. Int., 50, 273–279.

  • Sipos B, Moser S, Kalthoff H, Torok V, Lohr M and Kloppel G . (2003). Virchows Arch., 442, 444–452.

  • Skubitz KM, Campbell KD, Ahmed K and Skubitz AP . (1995). J. Immunol., 155, 5382–5390.

  • Sonenberg N and Gingras AC . (1998). Curr. Opin. Cell Biol., 10, 268–275.

  • Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA and Schiffmann E . (1989). J. Biol. Chem., 264, 21544–21549.

  • Streuli CH and Gilmore AP . (1999). J. Mammary. Gland. Biol. Neoplasia, 4, 183–191.

  • Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH and Testa JR . (2001). Cancer Res., 61, 589–593.

  • Tooze JA, Saso R, Marsh JC, Papadopoulos A, Pulford K and Gordon-Smith EC . (1995). Exp. Hematol., 23, 1484–1491.

  • Wu Y, Tewari M, Cui S and Rubin R . (1996). J. Cell Physiol, 168, 499–509.

  • Wu Y, Yakar S, Zhao L, Hennighausen L and LeRoith D . (2002). Cancer Res., 62, 1030–1035.

  • Yawata A, Adachi M, Okuda H, Naishiro Y, Takamura T, Hareyama M, Takayama S, Reed JC and Imai K . (1998). Oncogene, 16, 2681–2686.

  • Yoon A and Hurta RA . (2001). Mol. Cell. Biochem., 223, 1–6.

  • Zeng H, Datta K, Neid M, Li J, Parangi S and Mukhopadhyay D . (2003). Biochem. Biophys. Res. Commun., 302, 46–55.

  • Zhang D and Brodt P . (2003). Oncogene, 22, 974–982.

Download references

Acknowledgements

We gratefully acknowledge the technical assistance of Jan Rounds. This work was supported by The National Pancreas Foundation and departmental funds from the Department of Surgery, Brigham and Women's Hospital.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edward E Whang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duxbury, M., Ito, H., Benoit, E. et al. Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene 23, 5834–5842 (2004). https://doi.org/10.1038/sj.onc.1207775

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207775

Keywords

This article is cited by

Search

Quick links